Background Kidney transplantation in HIV-infected patients is characterized by a concerning high rate of allograft rejections. The etiological mechanisms leading to this increased immunoreactivity are still unknown. Maraviroc is a new antiretroviral agent that has been associated with immunomodulatory proprieties; therefore, its use may be a promising strategy to minimize the rate of rejections in HIV-infected kidney transplant (KT) recipients.Methods We conducted a retrospective study in our cohort of HIV-KT recipients with the aim to explore the effects of maraviroc in reducing the risk of graft rejection.Results Twenty-two HIV-infected KT recipients predominantly of Caucasian origin (86%) and with a median age of 49 (IQR, 51.9-42.2) years were evaluated. Ten HIV-infected patients were treated with maraviroc and 12 with a maraviroc-free antiretroviral regimen. After a median follow-up of 3.01 years, half of the maraviroc-treated patients (n = 5) developed seven episodes of graft rejection, most of them were T cell-mediated rejections (85.7%). Five episodes were recorded in the maraviroc-free group. The difference in the rate of graft rejections was not statistically significant (P = .23).Conclusions The administration of maraviroc was ineffective in preventing graft rejections in our cohort of patients.

Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients / Alfano, Gaetano; Guaraldi, Giovanni; Fontana, Francesco; Franceschini, Erica; Dolci, Giovanni; Mussini, Cristina; Cappelli, Gianni. - In: TRANSPLANT INFECTIOUS DISEASE. - ISSN 1398-2273. - 22:4(2020), pp. e13294-e13294. [10.1111/tid.13294]

Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients

Alfano, Gaetano;Guaraldi, Giovanni;Fontana, Francesco;Franceschini, Erica;Dolci, Giovanni;Mussini, Cristina;Cappelli, Gianni
2020

Abstract

Background Kidney transplantation in HIV-infected patients is characterized by a concerning high rate of allograft rejections. The etiological mechanisms leading to this increased immunoreactivity are still unknown. Maraviroc is a new antiretroviral agent that has been associated with immunomodulatory proprieties; therefore, its use may be a promising strategy to minimize the rate of rejections in HIV-infected kidney transplant (KT) recipients.Methods We conducted a retrospective study in our cohort of HIV-KT recipients with the aim to explore the effects of maraviroc in reducing the risk of graft rejection.Results Twenty-two HIV-infected KT recipients predominantly of Caucasian origin (86%) and with a median age of 49 (IQR, 51.9-42.2) years were evaluated. Ten HIV-infected patients were treated with maraviroc and 12 with a maraviroc-free antiretroviral regimen. After a median follow-up of 3.01 years, half of the maraviroc-treated patients (n = 5) developed seven episodes of graft rejection, most of them were T cell-mediated rejections (85.7%). Five episodes were recorded in the maraviroc-free group. The difference in the rate of graft rejections was not statistically significant (P = .23).Conclusions The administration of maraviroc was ineffective in preventing graft rejections in our cohort of patients.
2020
5-mag-2020
22
4
e13294
e13294
Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients / Alfano, Gaetano; Guaraldi, Giovanni; Fontana, Francesco; Franceschini, Erica; Dolci, Giovanni; Mussini, Cristina; Cappelli, Gianni. - In: TRANSPLANT INFECTIOUS DISEASE. - ISSN 1398-2273. - 22:4(2020), pp. e13294-e13294. [10.1111/tid.13294]
Alfano, Gaetano; Guaraldi, Giovanni; Fontana, Francesco; Franceschini, Erica; Dolci, Giovanni; Mussini, Cristina; Cappelli, Gianni
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1203159
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact